A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer’s mouse model

  title={A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer’s mouse model},
  author={Juliet K Knowles and Danielle A Simmons and Thuy-vi Nguyen and Lilith Vander Griend and Youmei Xie and Hong Zhang and Tao Yang and Julia Pollak and Timothy Chang and Ottavio Arancio and Marion S. Buckwalter and Tony Wyss-Coray and Stephen M Massa and Frank M Longo},
  journal={Neurobiology of aging},
  pages={2052 - 2063}

Figures from this paper

A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression

Targeting p75NTR is a promising approach to reducing AD-related degenerative processes that have progressed beyond early stages and is suggested to reduce and/or reverse fundamental AD pathologies in late-stage AD mice.

Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.

A role for p75NTR ligands in preventing fundamental tau-related pathologic mechanisms in AD is supported, and the development of these small molecules as a new class of therapeutic compounds is validated.

Immunization Against Specific Fragments of Neurotrophin p75 Receptor Protects Forebrain Cholinergic Neurons in the Olfactory Bulbectomized Mice

The approach based on immunological blockade of specific p75NTR sites, linked with the cytotoxicity, is a useful and effective tool for study of AD-associated mechanisms and for development of highly selective therapy of cholinergic malfunctioning in AD patients.

Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease

Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease

P021 is a neurogenic and neurotrophic compound which enhances dentate gyrus neurogenesis and memory processes via inhibiting leukemia inhibitory factor (LIF) signaling pathway and increasing brain-derived neurotrophic factor (BDNF) expression and has emerged as a highly promising compound for AD drug development.

Modulation of the p75 neurotrophin receptor suppresses age-related basal forebrain cholinergic neuron degeneration

The idea that modulation of p75NTR activity can prevent and potentially reverse age-associated BFCN degeneration is supported, and this may be achieved therapeutically with orally bioavailable agents such as LM11A-31.

A small molecule p75NTR ligand normalizes signalling and reduces Huntington’s disease phenotypes in R6/2 and BACHD mice

Results support small molecule modulation of p75NTR as an effective HD therapeutic strategy and LM11A-31 has successfully completed Phase I safety and pharmacokinetic clinical trials and is therefore a viable candidate for clinical studies in HD.

Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies

The hypothesis that modulation of p75NTR signaling inhibits a broad spectrum of Aβ-triggered, tau-related molecular pathology thereby contributing to synaptic resilience is supported.

Neurotrophin Receptor P 75 Modulation Effects On Alzheimer ’ s Disease * Corresponding

One of the first signs of disease Alzheimer's is the death of cholinergic neurons in the basal forebrain, which express the highest level of p75 in the adult brain, so that the study of this channel and modulation are interesting strategies for increasing the quality of life with this disease.



Small Molecule, Non-Peptide p75NTR Ligands Inhibit Aβ-Induced Neurodegeneration and Synaptic Impairment

These studies support an extensive intersection between p75NTR signaling and Aβ pathogenic mechanisms, and introduce a class of specific small molecule ligands with the unique ability to block multiple fundamental AD-related signaling pathways, reverse synaptic impairment and inhibit Aβ-induced neuronal dystrophy and death.

β-Amyloid1–42 Induces Neuronal Death through the p75 Neurotrophin Receptor

A novel mechanism to explain the early and characteristic loss of cholinergic neurons in the septohippocampal pathway that occurs in Alzheimer's disease is provided.

Hippocampal membrane-associated p75NTR levels are increased in Alzheimer's disease.

Using polyclonal and monoclonal antibodies against the p75(NTR) receptor's intra- and extracellular domains, it is shown that the mean level of membrane-associated p75-NTR in the hippocampus is significantly higher in human AD brains than in identical samples of hippocampal formation in age-matched non-AD human brains.

Signaling of the neurotrophin receptor p75 in relation to Alzheimer's disease.

Does the p75 neurotrophin receptor mediate Aβ‐induced toxicity in Alzheimer's disease?

This review focuses on the interactions between Aβ and p 75NTR in the context of the broader p75NTR signalling field, and offers alternative explanations for how p75nTR might contribute to the aetiology of Alzheimer's disease.

The p75 Neurotrophin Receptor Promotes Amyloid-β(1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo

Findings indicate that although p75NTR likely does not mediate all Aβ effects, it does play a significant role in enabling Aβ-induced neurodegeneration in vitro and in vivo, establishing p 75NTR as an important therapeutic target for AD.

The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system.

The p75 neurotrophin receptor (p75(NTR), a member of the tumor necrosis factor receptor superfamily, associates with the Nogo receptor, a binding protein for axonal growth inhibitors, and appears to be the transducing subunit of this receptor complex.

Cholinergic neuropathology in a mouse model of Alzheimer's disease

Data indicated that the homozygous PDAPP mouse exhibits cholinergic nerve terminal degenerative pathology and that the cortical neurodegenerative changes occur before the deposition of Aβ‐containing neuritic plaques.

Neuroprotective strategies in Alzheimer’s disease

It is likely that successful Alzheimer’s disease (AD) therapeutic regimens will require the concomitant application of neuroprotective agents, and candidates include those that interact specifically with neuronal targets to inhibit deleterious intraneuronal mechanisms triggered by Aβ and other toxic stimuli.

Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease.

Using rat cortical neurons and NIH-3T3 cell line engineered to stably express p75NTR, it is found that the beta-amyloid peptide specifically binds the p75 NTR, implying that neuronal death in Alzheimer's disease is mediated, at least in part, by the interaction of beta- amyloid with p 75NTR.